BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 25641676)

  • 1. Vaccination approach to anti-angiogenic treatment of cancer.
    Wentink MQ; Huijbers EJ; de Gruijl TD; Verheul HM; Olsson AK; Griffioen AW
    Biochim Biophys Acta; 2015 Apr; 1855(2):155-71. PubMed ID: 25641676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy.
    Kong DH; Kim MR; Jang JH; Na HJ; Lee S
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28817103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics.
    Hegde PS; Wallin JJ; Mancao C
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):117-124. PubMed ID: 29229461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer immunotherapy of targeting angiogenesis.
    Hou J; Tian L; Wei Y
    Cell Mol Immunol; 2004 Jun; 1(3):161-6. PubMed ID: 16219162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-angiogenic therapy: adapting strategies to overcome resistant tumors.
    Mitchell DC; Bryan BA
    J Cell Biochem; 2010 Oct; 111(3):543-53. PubMed ID: 20626031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nutraceuticals and their role in tumor angiogenesis.
    Rampino A; Annese T; Margari A; Tamma R; Ribatti D
    Exp Cell Res; 2021 Nov; 408(2):112859. PubMed ID: 34637764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy.
    Yetkin-Arik B; Kastelein AW; Klaassen I; Jansen CHJR; Latul YP; Vittori M; Biri A; Kahraman K; Griffioen AW; Amant F; Lok CAR; Schlingemann RO; van Noorden CJF
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188446. PubMed ID: 33058997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-angiogenic therapies in cancer: achievements and open questions.
    Ruegg C; Mutter N
    Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Resistance to anti-angiogenic therapy: a clinical and scientific current issue].
    Gu Y; Lu H; Boisson-Vidal C; Li H; Bousquet G; Janin A; Di Benedetto M
    Med Sci (Paris); 2016 Apr; 32(4):370-7. PubMed ID: 27137694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.
    Khan KA; Kerbel RS
    Nat Rev Clin Oncol; 2018 May; 15(5):310-324. PubMed ID: 29434333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor vasculature: the Achilles' heel of cancer?
    Johannessen TC; Wagner M; Straume O; Bjerkvig R; Eikesdal HP
    Expert Opin Ther Targets; 2013 Jan; 17(1):7-20. PubMed ID: 23121690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer.
    Missiaen R; Mazzone M; Bergers G
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):107-116. PubMed ID: 29935312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice.
    Bequet-Romero M; Ayala M; Acevedo BE; Rodríguez EG; Ocejo OL; Torrens I; Gavilondo JV
    Angiogenesis; 2007; 10(1):23-34. PubMed ID: 17273909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy.
    Gacche RN; Meshram RJ
    Biochim Biophys Acta; 2014 Aug; 1846(1):161-79. PubMed ID: 24836679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis inhibitors in cancer therapy.
    Dredge K; Dalgleish AG; Marriott JB
    Curr Opin Investig Drugs; 2003 Jun; 4(6):667-74. PubMed ID: 12901224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is VEGF a predictive biomarker to anti-angiogenic therapy?
    Otrock ZK; Hatoum HA; Musallam KM; Awada AH; Shamseddine AI
    Crit Rev Oncol Hematol; 2011 Aug; 79(2):103-11. PubMed ID: 20724177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.
    Tartour E; Pere H; Maillere B; Terme M; Merillon N; Taieb J; Sandoval F; Quintin-Colonna F; Lacerda K; Karadimou A; Badoual C; Tedgui A; Fridman WH; Oudard S
    Cancer Metastasis Rev; 2011 Mar; 30(1):83-95. PubMed ID: 21249423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.